Skip to main content

Complete Genomics and GATC Biotech Collaborate on Human Genome Sequencing Projects

News   •   Dec 01, 2009 15:44 GMT

GATC Biotech and Complete Genomics, Inc., today announced the execution of a research collaboration agreement to sequence several human genomes from samples provided by GATC. The companies will collaborate to analyze the data obtained from the research project. Complete Genomics will sequence and assemble the genomes and provide GATC with detected variants including single nucleotide polymorphisms (SNPs) and indels. GATC will then perform additional bioinformatics analysis such as comparison of the variant data of different genomes. In addition, the company will refine the data with the aim of providing researchers and clinicians with relevant genomic details to advance their understanding of the genetic causes of disease. The pilot project has started and the first sequencing data will be evaluated by GATC soon.

“GATC aims to continually offer our customers the most innovative, efficient and integrated sequencing technologies and applications for their research projects. To achieve our 100-Human-Genome-Project goal, evaluating Complete Genomics’ human genome sequencing technology is a logical step,” explains Peter Pohl, CEO of GATC Biotech.

“We are pleased to be working with GATC Biotech on this project which will further demonstrate the value of our large-scale, high-quality, low-cost human genome sequencing service,” said Dr. Clifford Reid, chairman, president, and CEO of Complete Genomics.

About Complete Genomics Founded in 2006, Complete Genomics is a California company that has developed a novel approach to sequencing human DNA that is revolutionizing the human genome sequencing industry. Complete Genomics combines its proprietary third-generation DNA sequencing technology with its high-performance computing capabilities to deliver low-cost, high-quality genomic data on an unprecedented scale. The company is currently building the world’s largest human genome sequencing center. This development will allow academic and biopharmaceutical researchers, for the first time, to conduct large-scale complete human genome studies that will help identify the genetic underpinnings of complex diseases and drug responses. For additional information about the company, please visit http://www.completegenomics.com.

Complete Genomics, Inc. | Jennifer Turcotte, Vice President of Marketing, Tel. (650) 943-2846, jturcotte@completegenomics.com

Comments (0)

Add comment

Comment